Skip to content

Treatment of chronic diabetic foot ulcers with Extracorporeal Shock Wave Therapy (ESWT) - a double-blind randomized controlled trial

Treatment of chronic diabetic foot ulcers with Extracorporeal Shock Wave Therapy (ESWT) - a double-blind randomized controlled trial - Shock Wave for diabetic foot ulcers

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON56830
Enrollment
54
Registered
2020-09-25
Start date
2020-06-01
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic diabetic foot ulcer footwound caused by diabetes

Interventions

The patients will receive 12 (placebo) ESWT treatments in addition to standard care. Standard care includes debridement, diabetic control, wound care, off-loading and footwear modification for press

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Age 18 years or older • Diabetes mellitus type I or 2 • Uni- or bilateral chronic foot ulcers which have not healed for 6 weeks • Grade 1A or 2A ulcer according to the Texas Diabetic Foot Wound Classification System • Diameter of the ulcer > 0.5 cm and 0.7 • Toe systolic pressure > 50 mmHg • Participants are mentally competent to understand and sign a Dutch informed consent form themselves

Exclusion criteria

Exclusion criteria: • History of neoplasia or malignancy near the chronic diabetic foot ulcer • Pregnancy • Skeletal immaturity which has an influence on the ability to walk • Sign of acute local infection demanding the use of systemic antibiotics or the need for amputation • Osteomyelitis or gangrene in the affected extremity • Severe anemia (Hb

Design outcomes

Primary

MeasureTime frame
The main study parameter is percentage of reduction in wound surface area

Secondary

MeasureTime frame
Secondary endpoints are time to complete healing, recurrence rate and quality of life.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)